- News Home
5 December 2013 11:26 am ,
Vol. 342 ,
An animal rights group known as the Nonhuman Rights Project filed lawsuits in three New York courts this week in an...
Researchers have been hot on the trail of the elusive Denisovans, a type of ancient human known only by their DNA and...
Thousands of scientists in the Russian Academy of Sciences (RAS) are about to lose their jobs as a result of the...
Dyslexia, a learning disability that hinders reading, hasn't been associated with deficits in vision, hearing, or...
Exotic, elusive, and dangerous, snakes have fascinated humankind for millennia. They can be hard to find, yet their...
Researchers have sequenced and analyzed the first two snake genomes, which represent two evolutionary extremes. The...
Snake venoms are remarkably complex mixtures that can stun or kill prey within minutes. But more and more researchers...
At age 30, Dutch biologist Freek Vonk has built up a respectable career as a snake scientist. But in his home country,...
- 5 December 2013 11:26 am , Vol. 342 , #6163
- About Us
Problems Mount for Novartis's Hypertension Drug in Japan
30 September 2013 1:15 pm
An investigative committee under Japan's ministry of health has confirmed that data in scientific papers resulting from clinical trials of Novartis's blockbuster hypertension drug Diovan were manipulated, several media outlets have reported today. In its interim report, the committee also called for further investigation to determine if Novartis's use of the data to promote the drug constitutes false advertising that is prohibited by Japan’s pharmaceutical laws, according to NHK, the quasi-national broadcaster.
The ministry of health launched its investigation in August after Kyoto Prefectural University of Medicine, in Kyoto, and Jikei University School of Medicine, in Tokyo, reported finding evidence of data fabrication in papers reporting the results of clinical trials of Diovan, known generically as valsartan, conducted after it received marketing approval in Japan in 2000 for controlling hypertension. Those clinical trials sought to study whether the drug also helped prevent angina and stroke. Both of the investigations found that a former Novartis employee helped the two universities’ research teams with data analysis, though that person's link to the company was not disclosed in the papers. The investigations led to the retraction of several papers related to the trials. The lead researcher at the Kyoto school resigned; the Jikei team leader was disciplined. Three other universities that hosted Diovan trials have ongoing investigations.
As in the previous probes, the health ministry panel could not conclude who bears ultimate responsibility for the data fabrication. Officials of Novartis, based in Basel, Switzerland, and Novartis Pharma KK, the Japanese subsidiary, have apologized and pledged their cooperation in the continuing investigation.